PBAC's latest decision on Golimumab; infliximab; ustekinumab: Deferred (2014). Considered for Amendment to authority requirements for continuing treatment with golimumab, infliximab, and ustekinumab for all PBS-reimbursed indications (including severe chronic plaque psoriasis, ulcerative colitis, and other approved indications). The submission requested a change from complex written authority to telephone authority for second and subsequent continuing prescriptions.
PBAC outcome
Deferred
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Patients who have already received initial and continuing therapy with golimumab, infliximab, or ustekinumab for PBS-reimbursed indications (including severe chronic plaque psoriasis, moderate to severe ulcerative colitis, and other registered indications).
Therapy area
Rheumatology
Line of therapy
Any
Evidence base
Other
Economic model
Not modelled
ICER note
No formal economic analysis was presented in the submission.